scholarly journals Coronavirus Vaccination Adverse Reactions and the Role of the Dermatologist

2021 ◽  
Vol 20 (3) ◽  
pp. 351-352
Author(s):  
Kayd Pulsipher ◽  
Colby Presley ◽  
Jacquelyn Waller ◽  
Mindy Szeto ◽  
Melissa Laughter ◽  
...  
Keyword(s):  
Adverse Reactions

Role of Adverse Reactions to Food in Urticaria and Exercise-Induced Anaphylaxis

2002 ◽  
Vol 129 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Sie-Uen Chong ◽  
Margitta Worm ◽  
Torsten Zuberbier
Keyword(s):  
Adverse Reactions ◽  
Exercise Induced

scholarly journals Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro

Blood ◽  
1983 ◽  
Vol 61 (5) ◽  
pp. 889-893 ◽  
Author(s):  
WT Gerson ◽  
DG Fine ◽  
SP Spielberg ◽  
LL Sensenbrenner
Keyword(s):  
Cell Viability ◽  
Aplastic Anemia ◽  
Adverse Reactions ◽  
Drug Metabolites ◽  
Peripheral Lymphocytes ◽  
Toxic Drug ◽  
Arene Oxide ◽  
Increased Susceptibility

A 53-yr-old man sequentially developed aplastic anemia from phenytoin and carbamazepine. Both compounds undergo metabolism to potentially toxic arene oxide intermediates. We tested the hypothesis that the patient's adverse reactions were due to a defect in detoxification of such metabolites by challenging his peripheral lymphocytes with drug metabolites generated by a murine hepatic microsomal system in vitro. The patient's cell viability was normal in the absence of drugs. However, his cells showed greater toxicity from both phenytoin and carbamazepine metabolites than did controls. Toxicity was dependent on microsomes and NADPH. Intermediate toxicity was noted in cells from the patient's mother. The results provide the first evidence for a role of arene oxide drug metabolites in aplastic anemia in humans and suggest that enhanced susceptibility to toxicity may be based on an inherited abnormality in metabolite detoxification.

Adverse Reactions to Iopamidol and Iohexol Myelography with Special Attention to Headache: Role of Myelographic Technique

1989 ◽  
Vol 29 (8) ◽  
pp. 519-522 ◽  
Author(s):  
David F. Sobel ◽  
Rekarda Rowe ◽  
Jack Zyroff ◽  
James A. Koziol ◽  
Francine Frost ◽  
...  
Keyword(s):  
Adverse Reactions

scholarly journals All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions

Vaccine ◽  
2021 ◽  
Author(s):  
Yihua Bruce Yu ◽  
Marc B. Taraban ◽  
Katharine T. Briggs
Keyword(s):  
Adverse Reactions ◽  
Potential Role

scholarly journals The Role of In Vitro Detection of Drug-Specific Mediator-Releasing Cells to Diagnose Different Phenotypes of Severe Cutaneous Adverse Reactions

2021 ◽  
Vol 13 (6) ◽  
pp. 896
Author(s):  
Jettanong Klaewsongkram ◽  
Supranee Buranapraditkun ◽  
Pattarawat Thantiworasit ◽  
Pawinee Rerknimitr ◽  
Papapit Tuchinda ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Severe Cutaneous Adverse Reactions ◽  
Cutaneous Adverse Reactions

scholarly journals The Role of Gut Microbiota in Tumor Immunotherapy

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Miao Wu ◽  
Jiawei Bai ◽  
Chengtai Ma ◽  
Jie Wei ◽  
Xianjin Du
Keyword(s):  
Immune System ◽  
Gut Microbiota ◽  
Intestinal Microbiota ◽  
Adverse Reactions ◽  
Tumor Development ◽  
Tumor Immunotherapy ◽  
Host Immune System ◽  
Hematological Tumors ◽  
New Research

Tumor immunotherapy is the fourth therapy after surgery, chemotherapy, and radiotherapy. It has made great breakthroughs in the treatment of some epithelial tumors and hematological tumors. However, its adverse reactions are common or even more serious, and the response rate in some solid tumors is not satisfactory. With the maturity of genomics and metabolomics technologies, the effect of intestinal microbiota in tumor development and treatment has gradually been recognized. The microbiota may affect tumor immunity by regulating the host immune system and tumor microenvironment. Some bacteria help fight tumors by activating immunity, while some bacteria mediate immunosuppression to help cancer cells escape from the immune system. More and more studies have revealed that the effects and complications of tumor immunotherapy are related to the composition of the gut microbiota. The composition of the intestinal microbiota that is sensitive to treatment or prone to adverse reactions has certain characteristics. These characteristics may be used as biomarkers to predict the prognosis of immunotherapy and may also be developed as “immune potentiators” to assist immunotherapy. Some clinical and preclinical studies have proved that microbial intervention, including microbial transplantation, can improve the sensitivity of immunotherapy or reduce adverse reactions to a certain extent. With the development of gene editing technology and nanotechnology, the design and development of engineered bacteria that contribute to immunotherapy has become a new research hotspot. Based on the relationship between the intestinal microbiota and immunotherapy, the correct mining of microbial information and the development of reasonable and feasible microbial intervention methods are expected to optimize tumor immunotherapy to a large extent and bring new breakthroughs in tumor treatment.

scholarly journals The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer

2020 ◽  
Vol 9 (6) ◽  
pp. 1918 ◽  
Author(s):  
Ramon Andrade De Mello ◽  
Nathália Moisés Neves ◽  
Giovanna Araújo Amaral ◽  
Estela Gudin Lippo ◽  
Pedro Castelo-Branco ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Adverse Reactions ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients ◽  
Phase Ii And Iii ◽  
Mesenchymal Epithelial Transition

Introduction: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients. Methods: We performed a literature search on PubMed in December 2019 for studies on MET inhibitors and NSCLC. Phase II and III clinical trials published in English between 2014 and 2019 were selected. Results: Data on MET inhibitors (tivantinib, cabozantinib, and crizotinib) and anti-MET antibodies (emibetuzumab and onartuzumab) are reported in the text. Conclusion: Emibetuzumab could be used for NSCLC cases with high MET expression. Further, studies on onartuzumab failed to prove its efficacy, while the results of tivantinib trials were clinically but not statistically significant. Additionally, cabozantinib was effective, but adverse reactions were common, and crizotinib was generally well-tolerated.

Sign in / Sign up

Export Citation Format

Share Document